Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

National Institute of Environmental Health Sciences

Use this QR code to view the newest version of this document
Use this QR code to view the newest version of this document

Your Environment. Your Health.

Publication Detail

Title: Identification and characterization of potent, selective, and efficacious inhibitors of human arylamine N-acetyltransferase 1.

Authors: Leggett, Carmine S; Doll, Mark A; Salazar-González, Raúl A; Habil, Mariam R; Trent, John O; Hein, David W

Published In Arch Toxicol, (2022 Feb)

Abstract: Arylamine N-acetyltransferase 1 (NAT1) plays a pivotal role in the metabolism of carcinogens and is a drug target for cancer prevention and/or treatment. A protein-ligand virtual screening of 2 million chemicals was ranked for predicted binding affinity towards the inhibition of human NAT1. Sixty of the five hundred top-ranked compounds were tested experimentally for inhibition of recombinant human NAT1 and N-acetyltransferase 2 (NAT2). The most promising compound 9,10-dihydro-9,10-dioxo-1,2-anthracenediyl diethyl ester (compound 10) was found to be a potent and selective NAT1 inhibitor with an in vitro IC50 of 0.75 µM. Two structural analogs of this compound were selective but less potent for inhibition of NAT1 whereas a third structural analog 1,2-dihydroxyanthraquinone (a compound 10 hydrolysis product also known as Alizarin) showed comparable potency and efficacy for human NAT1 inhibition. Compound 10 inhibited N-acetylation of the arylamine carcinogen 4-aminobiphenyl (ABP) both in vitro and in DNA repair-deficient Chinese hamster ovary (CHO) cells in situ stably expressing human NAT1 and CYP1A1. Compound 10 and Alizarin effectively inhibited NAT1 in cryopreserved human hepatocytes whereas inhibition of NAT2 was not observed. Compound 10 caused concentration-dependent reductions in DNA adduct formation and DNA double-strand breaks following metabolism of aromatic amine carcinogens beta-naphthylamine and/or ABP in CHO cells. Compound 10 inhibited proliferation and invasion in human breast cancer cells and showed selectivity towards tumorigenic versus non-tumorigenic cells. In conclusion, our study identifies potent, selective, and efficacious inhibitors of human NAT1. Alizarin's ability to inhibit NAT1 could reduce breast cancer metastasis particularly to bone.

PubMed ID: 34783865 Exiting the NIEHS site

MeSH Terms: Animals; Anthraquinones/pharmacology; Arylamine N-Acetyltransferase/antagonists & inhibitors*; Breast Neoplasms/drug therapy*; Breast Neoplasms/enzymology; Breast Neoplasms/pathology; CHO Cells; Cell Line, Tumor; Cell Proliferation/drug effects; Cells, Cultured; Computer Simulation; Cricetinae; Cricetulus; DNA Adducts/drug effects; DNA Breaks, Double-Stranded/drug effects; Enzyme Inhibitors/administration & dosage; Enzyme Inhibitors/pharmacology*; Hepatocytes/enzymology; Humans; Inhibitory Concentration 50; Isoenzymes/antagonists & inhibitors*

Back
to Top